0A4D Stock Overview
A clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
My Notes
Capture your thoughts, links and company narrative
Equillium, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.75 |
| 52 Week High | US$3.12 |
| 52 Week Low | US$0.59 |
| Beta | 1.77 |
| 1 Month Change | 0% |
| 3 Month Change | -18.85% |
| 1 Year Change | -14.40% |
| 3 Year Change | -78.51% |
| 5 Year Change | n/a |
| Change since IPO | -86.53% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0A4D | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 2.2% | -0.3% | 0.6% |
| 1Y | -14.4% | -24.5% | 4.6% |
Return vs Industry: 0A4D exceeded the UK Biotechs industry which returned -23.2% over the past year.
Return vs Market: 0A4D underperformed the UK Market which returned 4.6% over the past year.
Price Volatility
| 0A4D volatility | |
|---|---|
| 0A4D Average Weekly Movement | 23.9% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.6% |
| 10% least volatile stocks in GB Market | 2.5% |
Stable Share Price: 0A4D's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0A4D's weekly volatility (24%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 45 | Bruce Steel | www.equilliumbio.com |
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company’s lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications.
Equillium, Inc. Fundamentals Summary
| 0A4D fundamental statistics | |
|---|---|
| Market cap | US$27.16m |
| Earnings (TTM) | -US$4.61m |
| Revenue (TTM) | US$45.91m |
0.6x
P/S Ratio-5.9x
P/E RatioIs 0A4D overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0A4D income statement (TTM) | |
|---|---|
| Revenue | US$45.91m |
| Cost of Revenue | US$0 |
| Gross Profit | US$45.91m |
| Other Expenses | US$50.53m |
| Earnings | -US$4.61m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.13 |
| Gross Margin | 100.00% |
| Net Profit Margin | -10.05% |
| Debt/Equity Ratio | 0% |
How did 0A4D perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/08 11:08 |
| End of Day Share Price | 2025/01/06 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Equillium, Inc. is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Lut Ming Cheng | Cantor Fitzgerald & Co. |
| Raghuram Selvaraju | H.C. Wainwright & Co. |
| Biren Amin | Jefferies LLC |